Sign In
Buy IMMP
$0.377
+0.0030 (+0.80%)
At Close: Jun 22, 2026
Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti
12:02am, Friday, 20'th Mar 2020
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to report that it has been informed its Chinese partner, EOC Pharma, has completed patient recruitment for the o
The Non-Executive Director of Immutep Limited (ASX:IMM), Grant Chamberlain, Just Bought 38% More Shares
09:42pm, Tuesday, 17'th Mar 2020
Even if it's not a huge purchase, we think it was good to see that Grant Chamberlain, the Non-Executive Director of...
Immutep Receives Second IND approval for Efti from US FDA
12:00pm, Monday, 09'th Mar 2020
Enables Immutep to initiate its AIPAC-002 study, in metastatic breast cancerAIPAC-002 to expedite the possible use of efti for patients in the US SYDNEY, Australia, March 09,.
Immutep Reports Positive TACTI-002 Data
01:00pm, Wednesday, 19'th Feb 2020
Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1st line non-small cell lung cancer (NSCLC) patients and already 33% of.
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
12:21pm, Wednesday, 19'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex
The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
08:03pm, Sunday, 16'th Feb 2020
Biotech stocks were quiet in the week ending Feb. 14 amid some data readouts at a couple of conferences and earnings news flow from smid-cap companies. The following are key biotech catalysts to loo
Here's What We Think About Immutep Limited's (ASX:IMM) CEO Pay
02:53am, Tuesday, 11'th Feb 2020
Marc Voigt has been the CEO of Immutep Limited (ASX:IMM) since 2014. This report will, first, examine the CEO...
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
01:00pm, Tuesday, 04'th Feb 2020
SYDNEY, Australia, Feb. 04, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for.
Immutep Activities Report
01:00pm, Wednesday, 29'th Jan 2020
First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020More mature data expected from TACTI-002 in.
Analysts Offer Insights on Healthcare Companies: Immutep (NASDAQ: IMMP) and Sintx Technologies (NASDAQ: SINT)
12:35pm, Saturday, 11'th Jan 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immutep (IMMP – Research Report)
